ADVISORY, Aug. 17, 2007 (PRIME NEWSWIRE) --
What: Tony Cruz, Chief Executive Officer of Transition Therapeutics (TTHI) will preside over the opening bell in celebration of the company's listing on NASDAQ. Where: NASDAQ MarketSite - 4 Times Square - 43rd and Broadway - Broadcast Studio When: Monday, August 20, 2007 at 9:30 a.m. ET Contacts: Elie Farah Chief Financial Officer Transition Therapeutics Inc. Phone: 416-260-7770 x 203 efarah@transitiontherapeutics.com NASDAQ MarketSite: Jolene Libretto; (646) 441-5220; mobile - (347) 219-9539 Jolene.Libretto@NASDAQ.com
Feed Information:
The opening bell is available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Jolene Libretto at (646) 441-5220.
Radio Feed:
An audio transmission of the opening bell is also available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Waterfront fiber 1623 as well.
Webcast:
A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/reference/marketsite_about.stm.
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Transition Therapeutics (TTHI):
Headquartered in Toronto, Ontario, Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include AZD-103/ELND005 for the treatment of Alzheimer's disease and regenerative therapies E1-I.N.T.(tm) and GLP1-I.N.T.(tm) for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates developed using its proprietary drug discovery engine. Transition's shares are listed on the Toronto Stock Exchange under the symbol "TTH". For additional information about the company, please visit www.transitiontherapeutics.com.